13 May 2008
Intervet/Schering-Plough Animal Health Introduces EquiRab™ Vaccine
New equine vaccine provides long-lasting protection against deadly effects of rabies
MILLSBORO, Del. (May 13, 2008) – Intervet/Schering-Plough Animal Health announces the availability of EquiRab™, a rabies vaccine designed specifically for horses. The new vaccine for horses offers long-lasting protection against rabies in the convenience of a single, low-dose injection.
“Just as it is for dogs and cats, the potential for horse exposure to rabies justifies vaccination,” says Craig Barnett, D.V.M., Intervet Senior Equine Technical Services Veterinarian. “Although we don’t see a lot of clinical cases of rabies, vaccination against the disease should not be overlooked — especially because it is invariably fatal and has considerable public health significance.”
Rabies Vaccine Considered Core
The American Association of Equine Practitioners (AAEP) included rabies as a core vaccine in its recently updated vaccination guidelines, which provide veterinarians with current information and recommendations for vaccinating horses in their care.
“AAEP’s recent adoption of rabies as a core vaccine reiterates the significance of the disease as well as the efficacy and safety of vaccination, which has been determined to exhibit a high enough level of patient benefit and low enough level of risk to justify vaccination in the majority of horses,” says Barnett.
The Rabies Challenge
“While there only has been a handful of equid rabies cases reported within the last couple years, the number is increasing steadily. This is thought to be due in large part to the urbanization of areas where the disease is endemic in the wildlife population.”
Barnett says it is not uncommon for pastured or stalled horses to be unknowingly exposed to wildlife, and most of these incidences go unnoticed and most bite wounds are not found.
The rabies virus attacks the central nervous system of the horse and is very difficult to diagnose. Barnett says there is no definitive test to diagnose rabies in a live animal, further underscoring the need for preventive vaccination.
“Rabies vaccination is highly recommended,” says Barnett. “Clinical signs of equine rabies can mimic many other neurological diseases in the horse. Concern for rabies in a horse showing neurological signs can be somewhat minimized if the horse is known to have been vaccinated.”
Proven Safe and Effective
EquiRab is shown to provide long-lasting 14-month protection and is proven safe for use in healthy horses and foals 4-months of age or older. Field safety studies conducted by veterinarians in three states show that 97.7 percent of the 992 horses vaccinated with EquiRab had no injection site reactions or signs of adverse effects.
EquiRab features Intervet/Schering-Plough Animal Health’s proprietary adjuvant, Havlogen®, which aids in the consistency and potency of the vaccine. It also helps stimulate a better immune response and produces a booster effect for longer-lasting protection.
EquiRab is aseptically injected intramuscularly. Annual revaccination is recommended. A booster dose can be administered at more frequent intervals based upon individual horse or farm disease risk assessment, or anytime epidemic conditions exist or are reported.
EquiRab is available through veterinarians. For more information about EquiRab and the full line of Intervet equine products, contact Intervet Customer Service at 1-800-441-8272 or visit www.equirab.com or www.intervetusa.com.
For more information on the AAEP’s recently updated vaccination guidelines, visit www.aaep.org/vaccination_guidelines.htm.
Schering-Plough is an innovation-driven, science-centered global health-care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal-health products. Schering-Plough’s vision is to “Earn Trust, Every Day” with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
About Intervet/Schering-Plough Animal Health
Intervet is a leader in research and dedicated to the development, production and marketing of innovative, high-quality animal-health products and programs, such as Prodigy®, Prestige®, Encevac®, Flu Avert® I.N. Vaccines, Regu-Mate® (altrenogest), Panacur® (fenbendazole) POWERPAC, Banamine®(flunixin meglumine), and Intervet Foal Caresm program.
For more information visit: www.equirab.com or www.intervetusa.com
Prodigy, Prestige, Regu-Mate, Panacur, Encevac, Banamine, and Havlogen are registered trademarks, EquiRab is a trademark and Intervet Foal Care program is a service mark of Intervet Inc. or Schering-Plough Animal Health Corporation or an affiliate. Avert is a registered trademark of Heska Corporation.
© 2008 Intervet Inc. All rights reserved
For more information, contact:
Susan Conroy, 816-410-5158, or